Haemostatic status in patients with ovarian cancer compared with patients with benign ovarian cysts and the study of the relationships between haemostatic levels in ovarian cancer patients with known survival outcome by KOH CHEE LIANG, STEPHEN





HAEMOSTATIC STATUS IN PATIENTS WITH OVARIAN CANCER 
COMPARED WITH PATIENTS WITH BENIGN OVARIAN CYSTS 
AND 
THE STUDY OF THE RELATIONSHIPS BETWEEN HAEMOSTATIC  
























A THESIS SUBMITTED 
FOR THE DEGREE OF DOCTOR OF PHILOSOPHY, PhD 
DEPARTMENT OF OBSTETRICS AND GYNAECOLOGY 












I would like to acknowledge and express my sincere gratitude and thanks to the 
following.: 
Associate Professor Tham Kok Fun, Principal Investigator for the Project 
NMRC/0154/1996 ‘To study the haemostatic and fibrinolytic markers in 
gynaecological cancer especially ovarian cancer and the effects of chemotherapy’ in 
allowing me as a collaborator of the study and to write my thesis based on this 
project. 
 
Assistant Professor Razvi Khalil and the Oncology Group of the Obstetrics & 
Gynaecology Department for their assistance in recruiting and obtaining samples for 
the study. 
 
My colleagues in the Coagulation Laboratory; Ms Chua Seok Eng, Mr Yuen Wai 
Kong and Mdm Ng Bee Lian for their laboratory assistance. 
 
My supervisors: Research Associate Professor Ashim C Roy and Professor RNV 
Prasad for their advice and guidance during the course of my study. 
 
Professor Ng Soon Chye, former Head of the Department of Obstetrics and 
Gynaecology and present Head, Associate Professor P C Wong, for their consent and 
assistance in allowing me to use the facilities in the Department to pursue this course 
of study. 
 
The National University of Singapore in approving and allowing me to pursue this 











I DEDICATE this thesis to the memory of the late Emeritus Professor S Shan  
Ratnam, former Head of the Department of Obstetrics & Gynaecology (1970 – 1995) 
and Director of the School of Post-Graduate Medical Studies (1988 – 1999), Faculty 








































TABLE OF CONTENTS 
Title of thesis                    i 
Acknowledgements            ii  
Dedication                  iii 
Table of Contents           iv 
List of Figures           viii 
List of Tables            ix 
List of Publications/Conference Papers-arising from this study   xi 
Summary             xv 
Literature Review 
Chapter 1.1   The epidemiology of Ovarian Cancer  
 - Incidence and Mortality Trend 
 
1.1.1 Cancer Epidemiology                 2 
1.1.2 Incidence and Trends                 3 
1.1.3 Incidence of Ovarian Cancer in Singapore              7 
1.1.4 Histologic Type                           10 
1.1.5 Reproductive and Endocrine Factors                     11 
1.1.6 Oral Contraceptives and          12 
 Other Contraceptives        13 
1.1.7 Postmenopausal Estrogen Therapy                    13 
1.1.8 Talc          14 
1.1.8-1 Dietary Factors         14 
1.1.8-2 Mumps and Other Infectious Diseases     15 
1.1.8-3 Blood Group         15 
1.1.8-4 Inflammation         16
                            
1.1.9 Hereditary Factors          16 
1.1.10 FIGO Staging of Primary Carcinoma of the Ovary           19 
1.1.11 Mortality Trends in Ovarian Cancer                   21 
1.1.12 Mortality Trends in Singapore        28 
1.2 Blood Coagulation and Fibrinolysis 
-   Normal Haemostasis  
 
1.2.1 The theories of Blood Coagulation       30 
1.2.2 Nomenclature                       32 
1.2.3 Activation of Prothrombin                  32 
v) 
1.2.4 The theory of Seegers              35 
1.2.5 Coagulation cascade and fibrin formation by         36 
the intrinsic and extrinsic pathways    
 
1.2.6 Contact activation of Coagulation and Kinin system           36 
1.2.7 Endothelium and Coagulation            39 
1.2.8 The role of platelets in normal haemostasis           41 
  
Inhibitory Mechanisms 
1.2.9 Natural Inhibitors of Activated Clotting Factors          43 
1.2.10 Other Physiological Anticoagulants           44 
1.2.11 Thrombomodulin  (TM)               46 
1.2.12 Protein S              47 
1.2.13 Tissue Factor Pathway Inhibitor (TFPI)          47 
1.2.14 Tissue Factor Pathway Inhibitor 2 (TFPI-2)          48 
 
1.2.15 The Plasminogen (Fibrinolytic) System         49 
1.2.16 Cellular regulation of fibrinolysis          51 
1.2.17 Thrombin Activatable Fibrinolysis Inhibitor (TAFI)        52 
   
1.3 Blood Coagulation and Fibrinolysis 
- Haemostasis in Cancer          56 
 
1.3.1 Hypercoagulability and Thrombosis          57 
1.3.2 Pathogenetic Mechanisms            58 
1.3.3 Cell-cell Interactions             59 
1.3.4 Interactions with Blood Platelets             60 
1.3.5 Procoagulant Activity               62 
1.3.6 Tissue Thromboplastin            62 
1.3.7 Cancer Procoagulant (CP)                    63 
1.3.8 Thrombosis and Cancer                           63 
1.3.9 Intraoperative factors             64 




1.3.11 Components of the Plasminogen Activation System  
Relevant to Tumour Invasion and Metastasis           66 
1.3.12 Fibrinolytic Receptors (Annexin II)          67 
1.3.13 alpha-Enolase             67 
1.3.14 Urokinase Receptor (uPAR), PAI-1/2         67 
1.3.15 Fibrinolytic Proteins as Prognostic Indicators  
in Cancer              68 
1.3.16 Fibrinolytic System and Tumour Angiogenesis             70 
1.3.17 Blood Coagulation and Fibrinolysis  
in Gynaecologic Malignancy             71 
 
1.3.18 Incidence of DVT in Cancer             74 
Chapter 2 
Haemostatic Status in Patients with Ovarian Cancer Compared to 
Patients with Benign Ovarian Cysts and the Study of the Relationships 
between Haemostatic Levels in Ovarian Cancer Patients with Known 
Survival Outcome 
 
Objectives of the Thesis                           77 
Primary aims                           82 
Materials and Methods               83 
Validation of laboratory assays       87 
Results                       101 
- Haemostatic status in patients with ovarian cancer compared to  
patients with  benign ovarian cysts               103
   
- Relationship between age and systemic plasma haemostatic parameters 
  in preoperative plasma haemostatic parameters studied in pre-operative 
 ovarian cancer patients                  114 
 
- Plasminogen activators and inhibitors in ovarian tissue extracts           115 
 
- Characterization of plasminogen activators in euglobulin fraction 
 plasma and in ovarian tissue extracts 
 – fibrin zymography studies               120 
    
- The study of the relationships between haemostatic levels and disease         
outcome in ovarian cancer                 121 
 
- Relationships of plasminogen activators, inhibitors and uPAR levels  
in ovarian cancer tissue extracts and disease outcome             123 
vii) 
- Overall Survival Rate        126 
Discussion          128 
Appendix  – Laboratory assays and methods used  
1. Blood Coagulation Screening       140 
Computerized Thrombelastography    
2. Platelet Function        141 
(i) Platelet count,  (ii) ß-Thromboglobulin    
3. Coagulation Factors        142 
(i) Plasma fibrinogen,  
(ii) Factor VII         143
   
4. Activation of Coagulation       144 
(i) Prothrombin fragment 1+2 (F  1+2 )   
5. Coagulation Inhibitors       145 
             (i) Antithrombin III (functional) 
 (ii) Tissue Factor Pathway Inhibitor (TFPI)     147
    
6. Plasminogen (fibrinolytic) System and Proteins    148 
(i) Plasminogen (functional)  
(ii) fibrin D-dimer        150 
(iiia) t-PA activity         151 
      (iiib) t-PA antigen        152 
(iva) u-PA activity         153 
(ivb) u-PA antigen        154 
(v)   u-PAR         155
    
7. Plasminogen Activator Inhibitors      156 
(ia) PAI-1 activity        156 
(ib) PAI-1antigen         158 
(ii) PAI-2         159
  
8. Angiogenic Factor           160  
Human Vascular Endothelial Growth Factor  (VEGF) 
9. Fibrin Zymography        161 
10. Tissue extraction        162 
Glossary of Abbreviations        164 
 
References             165 - 217 
List of Figures 
Fig. 1.1-1.  Estimated numbers of cancer cases (1000s) in females by site  
        around 1990.           5 
Fig 1.1-2.   Ten most frequent cancers in females in Singapore, 1993-1997.    9 
 
Fig. 1.1-3.  Age-specific incidence of ovarian cancer in Singapore, 1993-1997.   10 
viii) 
 
Fig. 1.1-4. The four stages of Ovarian Cancer       20 
 
Fig. 1.1-5. Mortality from ovarian cancer in international selected countries,  
      1953-1987 (upper fig.). Countries that did not show a rise in mortality  
      and  (lower fig.) countries that did show a rise.      26 
 
Fig. 1.1-6. Five-year survival of patients with epithelial ovarian cancer in  
       Norway, 1975-1994, adjusted for age.      27 
 
Fig. 1.1-7. Age-specific ovarian cancer mortality in the Netherlands, 1954-1993.  27 
 
Fig. 1.2-1.  The ‘four-factor’ theory of blood clotting.     31 
 
Fig. 1.2-2.  A blood coagulation scheme based on existing evidence (1965),  
        including the autocatalytic effects of thrombin.     34 
 
Fig. 1.2-3.  Coagulation cascade and fibrin formation by the intrinsic and  
        extrinsic pathways.        38 
 
Fig. 1.2-4.  Plasma Kallikrein System.       39 
 
Fig. 1.2-5.  Diagrammatic illustration of Endothelium and Coagulation.   40 
 
Fig. 1.2-6.  The Protein C Anticoagulant Pathway.      45 
 
Fig. 1.2-7.  Schematic representation of the plasminogen (fibrinolytic) system.  50 
 
Fig. 1.2-8. A schematic presentation of mechanisms and regulation of  
       physiological fibrinolysis in the vascular system.    52 
 
Fig. 1.2-9.  The revised Intrinsic and Extrinsic Pathways of Blood Coagulation,  
        the Fibrinolytic and Kinin systems.      54 
 
Fig. 1.3-1.  Scheme of the activation of plasminogen by uPA.    66 
 
Fig. 1.3-2.  Schematic presentation of the fibrinolytic system.    68 
 
Fig   2-1.    Computerized Thromelastograph  (cTEG)     88  
 
Fig  2-2.     cTEG in various clinical states       88 
 
Fig 2-3.      cTEG in benign cyst and advanced ovarian cancer    89 
 
Fig 2-4.      Quality Control chart for ATIII                 100 
 





Fig 2-6.     The distribution of TEG evaluation                103
            
Fig 2-7.     The distribution of FVII, F1+2, and ATIII in benign cysts and cancer    104  
 
Fig 2-8.    The distribution of platelets, ß-TG, plasminogen and D-dimer levels      105 
 
Fig 2-9.    The distribution of t-PA, u-PA and PAI-1 levels               106  
 
Fig 2-10.  The distribution of plasminogen activators and uPAR levels in tissue 
      extracts of ovarian cance and benign ovarian cysts              115 
  
Fig 2-11.  Characterization of plasminogen activators in euglobulin fraction  
      plasma.                    120 
 
Fig 2-12. Characterization of plasminogen activators in ovarian tissue extracts.      120 
  
Fig 2-13. The distribution of ATIII, D-dimer and plasminogen levels and  
     their association with disease outcome in ovarian cancer. The mean  
     levels of those still living (n=10) past 36 months from disease are    
     indicated.         124 
Fig 2-14.  Kaplan Meier plots for cumulative survival rates for ATIII and  
     D-dimer levels within 36 months of ovarian cancer. Median levels and 
     the number of events and overall survival rate outcome shown.             125
       
Fig. 2-15. Kaplan-Meier plot for survival rate in ovarian cancer patients who are 
     still living at 36 months (n=11) after diagnosis. Survival rate at  
     12 months = 66.7%, 24 months = 51.9% and at 36 months = 40.7%.  127 
 
 
List of Tables 
 
Table 1.1-1. The annual age-standardized incidence rate (per 100,000) of ovarian 
           cancer of selected countries in the five continents between  
          1988-1992.            6 
 
Table 1.1-2.  Cancer Incidence in Singapore, 1968 – 1997.        8 
 
Table 1.1-3.  Incidence of ovarian cancer in Singapore, 1968 – 1997.      9 
 
Table 1.1-4. FIGO staging of primary carcinoma of the ovary.     19 
 
Table 1.1-5. Age-standardized (65-84 years, world standard) death certification 
          rates per 100,000 women from ovarian cancer in various countries,  
         1955-1992.          25 
 
Table 1. 2-1. Blood clotting factors and inhibitors.       33 
 
Table 1.3-1. Possible mechanisms of blood clotting activation in cancer.    59 
x) 
 
Table 2-1.   Blood and tissue samplings from ovarian cancer and benign cysts  
        studied and comparison of age between benign cysts and ovarian  
        cancer patients.           84 
 
Table 2-2    Disease outcome of patients with ovarian cancer from hospital 
         records of their last visit at time of statistical analysis.     102 
 
Table 2-3. Thromboelastography (TEG), fibrinogen, Factor VII and F 1+2  
       levels in ovarian cancer compared to patients with benign ovarian  
       cysts.         108  
 
Table 2-4. Antithrombin III, plasminogen, D-dimer levels and platelet function  
      in ovarian cancer compared to patients with benign ovarian cysts. 109 
 
 
Table 2-5. Systemic Vascular Endothelial Growth Factor (VEGF) and Tissue  
       Factor Pathway Inhibitor (TFPI) in ovarian cancer compared to  
       patients with benign ovarian cysts.     110 
 
Table 2-6. Systemic plasminogen activators (t-PA and u-PA), PAI-1 and  
       uPAR in ovarian cancer compared to patients with benign ovarian  
       cysts.         111 
 
Table 2-7.  Comparison of systemic levels of plasminogen activators, PAI-1  
        and u-PAR between advanced and early stage ovarian cancer.              112
          
Table 2-8. Comparison of Thrombelastography (TEG) and systemic levels 
       of fibrinogen, Factor VII and F 1+2 between advanced and early  
       ovarian cancer.         112 
 
Table 2-9. Comparison of systemic levels of TIII, plasminogen, D-dimer,  
       platelets, and ß-TG between advanced and early ovarian cancer. 113 
 
Table 2-10. Significant relationships between haemostatic parameters studied  
        and age in ovarian cancer patients.     114 
 
Table 2-11. Plasminogen activators (t-PA and u-PA), PAI-1 and u-PA receptor 
        levels in tissue etracts of ovarianc cancer and benign ovarian cysts.      116 
 
Table 2-12. Plasminogen activators, inhibitors aand uPAR levels in primary 
         tumour extracts of early and advanced ovarian cancer.   118 
 
Table 2-13. Relationship of haemostatic parameters associated with mortality 
         outcome by 12 months, 24 months and 36 months compared to  






List of Publications/ Conference Papers arising from this study 
 
Publications: Ovarian cancer study 
 
Stephen CL Koh, K-F Tham, K Razvi, P-l Oei, F-K Lim, A-C Roy, RNV Prasad. 
Hemostatic and fibrinolytic status in patients with ovarian cancer and benign ovarian 
cycst. Could D-dimer and antithrombin III levels be included as prognostic markers 
for survival-outcome?  Clinical and Applied Thrombosis/Hemostasis  2001, 7(2): 
141-148.  
Stephen CL Koh. Markers of plasminogen (fibrinolytic) system in ovarian cancer. 
Sing J Obstet & Gynae  2000, vol 31 (1) 5-12,. 
 
Publications: Validation of assays performed in this study 
 
Koh SCL, FHM Tsakok, SS Ratnam. The influence of pH on the level of plasminogen  
activator activity as measured by the Euglobulin Clot Lysis Time and by the fibrin 
plate method. S’pore J Obstet & Gynaecol 1982; 13: 206-214. 
 
Koh SCL, R Yuen, OAC Viegas, SE Chua, BL Ng, DK Sen and SS Ratnam. A 
plasmin generation method for the determination of tissue plasminogen activator     
(t-PA) activity in blood. Immunol Cell Biol 1989; 67: 197 – 203. 
 
Koh SCL, R Yuen, OAC Viegas, SE Chua, BL Ng, DK Sen, SS Ratnam. Plasma 
tissue plasminogen activator inhibitor (t-PAI) activity in normal subjects. Med Sci 
Research 1989a; 17: 135 – 136. 
 
Koh SCL, PC Wong, R Yuen and SS Ratnam. Fibrin zymography of plasminogen 
activators in the human endometrium. J Med Lab Scs  1988; 2: 14 –16. 
 
Koh SCL, Yuen R, Viegas OAC, Chua SE, Ng BL, Sen DK, Ratnam SS.  
Plasminogen activators tPA, uPA and its inhibitor (PAI) in normal males and 
females. Thromb Haemost 1991; 66: 581-585. 
 
Koh SCL, Wong PC,  Yuen R, Chua SE, Ng BL,  Ratnam SS.  Concentration  of  
xii) 
plasminogen activators and inhibitor in the human endometrium at different phases of 
the menstrual cycle. J Reprod Fert 1992; 96: 407-413. 
 
Koh SCL, R Yuen, OAC Viegas and SS Ratnam. Plasma urokinase activity and 
antigen levels in normal males, females and in late pregnancy. Med Sci Research 
1992; 20: 601 – 602. 
 
Koh SCL, C Chew, OAC Viegas, BL Ng, SE Chua, R Yuen, M Choo, SS Ratnam. 
Thrombelastography in normal subjects and in various clinical states. J Med Lab Scs 
1993; 7 (1): 29 – 34. 
 
Koh SCL, Anandakumar C, Montan S, Ratnam SS. Plasminogen activators, 
plasminogen activator inhibitors (PAIs) and markers of intravascular coagulation in 
preeclampsia. Obstet & Gynecol 1993; 35: 214-221. 
 
Koh SCL, Boey ML, Ratnam SS, Viegas OAC. Plasminogen activators and 
inhibitors, D-dimer and ß-TG in systemic lupus erythematous pregnancy in relation to  
their obstetric outcome. J Obst & Gynaecol 1996; 16: 496-504. 
 
Koh SCL, WK Yuen, BL Ng, S Arulkumaran. Thrombelastographic determination of 
calcium threshold for blood coagulation in vitro. J Med Tech Assoc Thailand 1996; 
24(1): 25 – 33. 
 
Koh SCL, Dramusic V, Ratnam SS. The effects of long-term hormone-replacement 
therapy on coagulation, fibrinolysis and inhibitors in postmenopausal women. Int J 
Gynecol Obstet 1998a; 62: 279-285. 
 
Koh SCL, S Arulkumaran, A Biswas, SS Ratnam. The influence of labor and 
placental separation on hemostasis in term pregnancy. Clin Appl Thromb/Hemost 
1998b; 4: 262-267. 
 
Yin KH, Koh CLS, Malcus P, Montan S, Biswas A, Arulkumaran A, Ratnam SS. 
Preeclampsia: haemostatic status and the short term effects of methyldopa and  
xiii) 
isradipidine therapy. J Obstet Gynae Res 1998; 62: 270-285. 
 
Koh SCL,  OAC Viegas  and  SS Ratnam.  A  prospective  study  on  the  effects  of  
reformulated 2-rod Norplant implant on haemostasis after five years of use. J Obstet 
Gynaecol Res 1999a; 25: 177-183. 
 
Koh SCL,  C Anandakumar, A Biswas. Coagulation and fibrinolysis in viable mid-
trimester pregnancies of normal, intrauterine growth retaradation, chromosomal 
anomalies and hydrops fetalis and their eventual obetric outcome. J Perinatal Med 
1999b; 27: 458-464. 
 
Conference papers: Ovarian cancer study 
 
Khalil R, Koh CL Stephen, Lim FK, Ilancheran A. Antithrombin III and D-dimer 
levels are associated with disease outcome compared to those still living past 36 
months from ovarian cancer. 16th International Congress of the International Society 
for Fibrinolysis and Proteolysis (ISFP) 08-13 September 2002, Munich, Germany. 
 
Stephen CL Koh. Haemostatic markers in ovarian cancer. Invited Speaker 
Symposium “ New Markers and Techniques in Pathology” 7th Asian Pacific 
Association of Societies of Pathologists, 18-23 November 2001, Singapore.  
 
Koh CL Stephen, Tham KF, Khalil R, Oei PL, Lim FK, Chua SE, Yuen WK, Ng BL, 
Roy AC, Prasad RNV. Enhanced fibrinolysis and thrombin generation in ovarian 
cancer patients with than without metastasis. XVth International Congress on 
Fibrinolysis & Proteolysis 25-29 June , 2000, Hamamatsu, Japan. Fibrinolysis & 
Proteolysis 14 (suppl 1) June 2000 Abstract 0-97. 
 
Stephen CL Koh (Invited Speaker). Markers of plasminogen (fibrinolytic) system and 
ovarian cancer.  Abstract 8-26, Satellite Symposium, XVth International Congress on  
Fibrinolysis & Proteolysis 23-26 June 2000, Hamamatsu, Japan. Fibrinolysis & 




BL Ng, Oei PL, Tham KF. Chua SE, WK Yuen, Stephen CL Koh. The use of citrate-
plasma for CA125 assay in epithelial ovarian cancer. 8th Asian Conference in 
Medical Laboratory Technology, 5-9 September 1999, Brunei Darussalam. 
 
Stephen CL Koh, KF Tham, FK Lim, PL Oei, Ratnam SS, Chua SE, WK Yuen, BL 
Ng. Fibrinolytic proteins and inhibitors in ovarian cancer tissues compared with 
benign ovarian cysts.  Thrombosis & Haemostasis (Aug suppl). Abstract 532. XVIIth 
Congress of the International Society for Thrombosis & Haemostasis 14-21 Aug 
1999. Washington DC, USA.  
 
Koh CL Stephen, Tham KF, Oei PL, Lim FK, Chua SE, Yuen WK, Ng BL, Roy AC, 
Prasad RNV. Coagulation, plasminogen activators and inhibitors in patients with 
advanced ovarian cancer and benign ovarian cysts. Thrombosis & Haemostasis (Aug 
suppl). Abstract 531. XVIIth Congress of the International Society for Thrombosis & 
Haemostasis 14-21 Aug 1999. Washington DC, USA. 
 
 
Stephen CL Koh, KF Tham, K Razvi, FK Lim, PL Oei, SS Ratnam.  Preliminary 
study of uPAR and plasminogen activators and inhibitors in tissues from benign and 
ovarian cancer. Third Singapore Congress in O &G, 17-21 July 1998 Singapore. 
 
Stephen CL Koh, KF Tham, K Razvi, FK Lim, PL Oei, SS Ratnam. Preliminary 
study of uPAR and plasminogen activators and inhibitors in tissues from benign and 
ovarian cancer. Fibrinolysis & Proteolysis 12 (suppl 1) Abstract 248, 1998. 14th Int 










    Ovarian cancer is one of the more severe gynaecological malignancies known in 
women as it has a long asymptomatic course and usually presents at an advanced 
stage at time of diagnosis. The five-year survival rate is between 30% to 40%.  
   Sub-clinical abnormalities of haemostasis have been reported in cancer with an on-
going low-grade disseminated intravascular coagulation. A comparative systemic 
study of  36 patients with preoperative ovarian cancer and 35 patients with benign 
ovarian cysts showed hypercoagulation, increased platelets, platelet activation and 
enhanced fibrinolysis in ovarian cancer. Elevated tissue-plasminogen activator (t-PA) 
antigen, plasminogen activator inhibitor-1 (PAI-1) antigen and urokoinase-like 
plasminogen activator receptor (u-PAR) were also seen. Tissue Factor Pathway 
Inhibitor (TFPI) which play a role in the inhibition of Tissue Factor induced 
coagulation were significantly raised in ovarian cancer patients compared to patients 
with benign ovarian cysts. In advanced ovarian cancer further enhanced thrombin 
generation were evident by significantly reduced antithrombin III (ATIII) levels and 
elevated D-dimer level indicating enhanced fibrinolysis. 
     There is increasing evidence to suggest associations between fibrinolytic system 
and cancer especially the primary tumour. In this study of  23 ovarian cancer and 18 
ovarian benign tissue extracts, significant upregulation of u-PA antigen and PAI-1 
antigen were seen in ovarian cancer compared with benign ovarian cysts. There were 
no significant differences between early stage and advanced stage of cancer in the 
fibrinolytic and inhibitor parameters studied, except increased t-PA activity level in 
advanced ovarian cancer. Furthermore,no significant association of haemostatic levels   
in primary  tumour  extracts  with  disease outcome  was  found  when  compared with   
xvi) 
mortality with those still living past 36 months from disease. In the systemic 
circulation, haemostatic parameters studied were not correlated with disease outcome 
when mortality within 12 months, 24 months and 36 months were compared  with 
those still living past 36 months except for clotting time, ATIII, plasminogen and D-
dimer levels. Significant relationships of haemostatic parameters with age were seen 
in those above 50 years old who had higher levels of t-PA antigen and beta-
thromboglobulin (ß-TG). 
    Fibrin zymography demonstrated the presence of single-chain t-PA and u-PA in 
both plasma and tissue extracts in benign cysts and ovarian cancer cohorts.  
    Out of the total of 38 patients with ovarian cancer recruited into the study, 16  
patients died within 35 months from disease. The survival rate for ovarian cancer at 
12 months was 66.7%, at 24 months 51.9% and 40.7% at 36 months. Eleven patients 
at the time of analysis is still living between 36 months and 59 months from the 
disease. Mortality was mainly due to advanced stage of cancer except one (Stage IC) 
who had other complications.  
     From this study it appears that survival outcome favours those with preoperative 
normal ATIII and D-dimer levels especially in early ovarian cancer and had 
chemotherapy. ATIII and D-dimer levels could be included with known FIGO 
(Federation of International Gynaecology and Obstetrics) stage prognosis as systemic 
prognostic markers for survival outcome at least for the first 36 months of disease. 
The outcome of this study justifies the concept of treating patients with anticoagulant 
drugs preferably low molecular weight heparin (LMWH) to improve the prognosis or 

















The Epidemiology of Ovarian Cancer 
 

























The Epidemiology of Ovarian Cancer 
 
Cancer Aetiology 
    Aetiology and epidemiology are often associated with each other. Chemicals and 
radiation are two agents now clearly shown to cause cancers in humans whilst 
viruses are highly suspect on the basis of our present knowledge. The objective of 
cancer aetiology is cancer prevention. 
 
1.1.1 Cancer Epidemiology 
    Epidemiological research has strongly suggested that variations in social habits and 
exposure to environmental agents have led to variations in the incidence of cancers 
among the various groups of population. The relationship between man and his 
environment and the long latent period of cancer development has contributed to the 
complexity and identification of cancer inducing factors difficult (Barber 1992).    
    Ovarian cancer is an important cause of morbidity and mortality, especially in 
middle-aged women.  It is the sixth most common site of cancers in women after 
breast, lung, colon, rectum and endometrium (Harlap 1993).  Ovarian cancer affects 
about 4% of half a million women diagnosed each year with cancer in the United 
States (National Cancer Institute 1989) and between 3 and 7% of women in other 
countries (Parkin et al 1988). The great majority of ovarian cancers are epithelial in 
origin with incidence increased sharply and peaks at ages 65 to 75 years whilst the 
uncommon germ-cell tumours showed peak incidence in women aged between 15 and 
34 years.  
    The precise cause of epithelial ovarian cancer estimated to account for 80 to 90% of  
all  ovarian  carcinomas  (Baylis et al 1986) is not known but a number of 
epidemiologic factors have been suggested to be associated with ovarian cancer. 
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Among them are nulliparity, infertility, marked premenstrual strain, abnormal breast 
swelling, marked dysmenorrhoea, increased abortion rate, early menopause, group A 
blood, irradiation of pelvic organs, environmental factors, industrial products, socio-
economic status, celibacy, breast cancer and resistant to mump parotitis (Barber 
1992). In epithelial ovarian cancer, circumstantial evidence suggested by the 
reproductive profile of women at highest risk indicates that repititive ovulation is 
involved in the pathophysiology of the disease. A novel hypothesis suggesting that 
inflammation is the common mechanism underlying this disease (Ness & Cottreau 
1999). Pregnancy and the use of oral contraceptive pill seem to have a protective 
effect for ovarian cancer was reported (Joly DJ et al 1974; McGowan et al 1979; 
Hildreth NG et al 1981; Rosenbergh et al 1982; Risch et al 1983) and also for parity 
(Negri et al 1991). 
 
1.1.2 Incidence and Trends 
   The annual incidence of ovarian cancer varies considerably throughout the world. 
The highest rates are found in industrialised countries except Japan. In Scandinavian 
countries the incidence was between 13.9 and 15.3/100,000 women per year (Muir et 
al 1987), whereas in Miyagi, Japan it was 3.2/100,000 (Lingeman 1983). However, 
residents from low incidence countries like Japan who migrated to the United States 
develop  a risk similar to that of native-born Americans after living in the United 
States for one to two generations (Buell & Dunn 1965; Haenszel & Kukihara 1968) 
suggesting the  important  contribution of  environmental  factors. In Europe, a north 
to south gradient age-adjusted incidence from Scandinavian countries to intermediate 
incidences in the United Kingdom, France, Switzerland and Germany of between 7.8 
and  13.2/100,000  women  and countries  bordering  the Mediterranean, the incidence  
4 
was between 5.4 and 11.7/100,000. In the Netherlands it was 14.9/100,000 between 
1989 and 1991 and decreased to 11.4/100,000 in the period 1989 to 1993 (Koper et al 
1996). Similarly in Norway, the incidence of ovarian cancer rose until mid-1980s and 
stabilized thereafter (Bjorge et al 1997). A reverse trend of incidence from south to 
north gradient was seen in South America (Parkin et al 1988). In the United States, 
the annual incidence is 12-13 per 100,000 women which is similar to Canada (Muir et 
al 1987, Ayiomamitis 1989). Among Chinese women, ovarian cancer was 
documented as 5.0 and 5.8 /100,000 in Shanghai and Hong Kong respectively, and 
8.5/100,000 in the Chinese in San Francisco compared to the Bay Area Caucasians’ of 
12.9/100,000 (Muir et al 1987). In the United States, the age-adjusted incidence of 
ovarian cancer in 1987-1991 was 14.8/100,000 (Ries et al 1998). The incidence was 
higher in whites compared to blacks and the differences diverge progressively with 
increasing age (National Cancer Institute 1989). Asian-American women were lowest 
among Native American women (Ries et al 1998). Blacks showed incidence of higher 
rates of ovarian cancer than whites below 45 years of age (Weiss et al 1977). In Israel, 
the incidence of  ovarian  cancer  in   Jewish   emigrants  from  Europe  and  the 
Americas is among the highest in the world (Parkin 1989; Steinitz et al 1989), with 
European-born Jews having an incidence rate of 17.2/100,000 (Roush et al 1987).  In 
contrast,  the Jewish emigrants from North Africa and Asian near East region where 
fertility is high is associated with lower incidence of the disease (Steinitz et al 1989). 
The age-standardized annual incidence rate of ovarian cancer in the five continents 
between 1988 and 1992 is shown in Table 1-1 and the worldwide burden of cancer in 
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Table 1.1-1. The annual age-standardized incidence rate (per 100,000) of ovarian 
cancer of selected countries in the five continents between 1988 and 1992. 
 
     No.   ASR                      No.       ASR 
                    (all ages)                 (all ages) 
 
Africa:          Oceania 
Uganda Kyadondo 48        6.6      Australia, New South Wales      1654         8.4 
                                                                             New Zealand, non-Maori           1125 11.0 
Americas: Central and South               New Zealand, Maori                  68 12.2 
Argentina, Concordia   26        7.6      USA, Hawaii, White   122 14.2 
Brazil, Porto Alegre         183        8.4      USA, Hawaii, Hawaiian    36   8.3 
Colombia, Cali              268        8.9      USA, Hawaii Chinese     18   6.6 
Costa Rica              330        5.9      USA, Hawaii Japanese        95         8 
  
Ecuador, Quito              146        6.3 
Peru, Lima              296        6.0      Asia 
Uruguay, Montevideo      300        9.8      China, Shanghai               1321   5.8 
                                                                             China, Tianjin                     535   5.3 
North America         Hong Kong                1164         7.4 
Canada             9793      10.5      India, Bombay                  989         7.2 
Canada, Yukon            17       19.9      India, Madras                  390   5.7 
US, San Francsico Bay Area                               Israel: All Jews  1299 11.6 
  (non-Hispanic white)    1164      13.2         Israel: born in America/Europe    778 13.5 
  (Hispanic –white)            109       9.9      Israel: born in Africa/Asia     261   7.3 
  (Black)                125       9.5      Israel: non Jews      37   3.0 
  (Chinese)                 66       7.8      Israel:Jews born in Israel              255 12.4 
  (Japanese)                 16       7.4      Japan, Miyagi    494   6.1 
US, Iowa             1359     12.0      Japan, Osaka   1722   5.6 
US, Conneticut White      1383     11.6      Korea, Kangwha        8        2.8 
                         Black   47       7.0       Kuwait: Kuwaitis      25   4.7 
          Philippines, Manila    692   9.4  
Europe           Singapore: Chinese      585 10.7 
Austria, Tyrol              366       15.1                      Malay      80   9.9 
Czech Republic            5082       13.3            Indian      28   7.5 
Denmark            2874       14.0      Thailand, Chiang Mai    152   4.4 
Finland             2656       10.9      Vietnam, Hanoi (1991-1993)     82   2.9 
France, Isere              310         9.1 
Germany, East            3356       12.2  
Germany, Saarland           514         9.6  
Iceland    89       10.9 
Ireland, Southern              220       13.6      
Italy, Florence              411         9.4 
Italy, Genoa              360         9.7 
The Netherlands            5013       11.2 
Norway             2214       13.3     from: Parkin et al (eds).  
Poland, Warsaw              726       13.3.    ‘Cancer Incidence in five countires’  
Slovenia               766       10.5.     vol VII, IARC Sci Publ no. 143, 1997 
Sweden             4755       13.2 
Spain, Basque County      481         7.7 
Switzerland, Geneva        201       11.9 
UK, England & Wales 15483       12.4 
UK, Scotland           2844       13.3 
ASR = age-standardized rate 
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    The incidence of ovarian cancer has remained stable over the last three decades in 
high risk developed countries, whereas in the underdeveloped countries the incidence 
has been reported to be increasing (Adami et al 1990, Parazzini et al 1991a). The 
documented increase could be due to improved medical care and reporting. 
 
1.1.3 Incidence of Ovarian Cancer in Singapore 
    In Singapore, the cancer incidence in the females increased from 42% during the 
period 1968-72(n=5,099); 48.4% between 1988-92 (n=12,748) to 49.3% between 
1993-7 (n= 15,679)(Table 1.1-2). The incidence of ovarian cancer saw a sharp rise 
from 222 cases in 1968-72 (Lee et al 1988) to 880 cases in 1993-97 (Chia et al 1996, 
2000). It was the seventh most frequent cancers in females and from 1978-92 became 
sixth with incidence of 5.5% (1988-92) and 5.6% (1993-7) of all cancers in females. 
Breast cancer remains the most frequent cancer site with an incidence of 20.5% 
(1968-92) and 22.8% (1993-7) of all cancers in females (Chia et al 1996, 2000). The 
age-adjusted rate of incidence for ovarian cancer was 6.0/100,000 between 1968-72, 
10.5/100,000 (1988-92) and rose to 11.4/100,000 (1993-7). Between 1988 and 1992 
the highest incidence occurred in ethnic Chinese females (10.7) compared to Malay 
(9.9) and Indian women (7.5/100,000 per year)(Chia et al 1996). Ovarian cancer in 
Malays remain the most frequently diagnosed malignancy and is one of the few 
cancers which appears to have a higher risk than in Chinese (Chia et al 2000).  The 
ovarian cancer incidence rate in Singapore falls between those of Western Europe and 
the rest of Asia. The incidence of this cancer showed a steady increase over time 
whilst stable or decreasing trends are observed in many developed countries. The age- 
and  ethnic-adjusted   relative  risk  for  the  period  1988 and 1992  was 1.7 times that  
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observed between 1968 and 1972  (Chia et al 1996).  Cancer incidence and incidence 
of ovarian cancer in Singapore between 1968 and 1997 are shown in Tables 1.1-2 and 
1.1-3. The frequency of ten most frequent cancers in females between 1988 and 1992 
are shown in Fig 1.1-2 with age-specific incidence of ovarian cancer between 1993 
and 1997 in Fig 1.1-3.   
 
Table 1.1-2.  Cancer Incidence in Singapore, 1968 - 1997. 
 
Period  Sex       Number       %             CR   ASR 
1968 - 72 Male       7,029      58.0 136.3  229.3 
  Female      5,099      42.0 103.7  154.5 
1973 - 77 Male       8,578      58.0 158.4  247.5 
  Female      6,204      42.0 119.2  161.6 
1978 - 82 Male     10,131      55.9 175.0  250.3 
  Female      8,004       44.1 142.8  176.0 
1983 - 87 Male     11,649      53.7 186.6  242.3 
  Female    10,026      46.3 165.2  182.9 
1988 - 92 Male     13,583      51.6 198.0  235.8 
  Female    12,748      48.4 190.7  191.8 
1993 – 97 Male      16,150      50.7 209.7  233.1 
  Female    15,679      49.3            208.8  198.1 
 
CR: Crude rate (per 100,000/year);   ASR:   Age-standardised rate (per 100,000/year) 
from: Chia KS, Lee HP, Seow A and Shanmugaratnam K. Trends in cancer incidence in 
Singapore 1968/1992 and Cancer Incidence in Singapore 1993-1997.  Published by 










Table 1.1-3. Incidence of Ovarian Cancer in Singapore, 1968 – 1997. 
 
 Year           No.       Age-standardised rate (per 100,000/year) 
1968 – 1972         222  6.0 
1973 – 1977         263   6.3 
1978 – 1982         411  8.6 
1983 – 1987         497  8.8   
1988 – 1992         702           10.5 
1993 – 1997         880           11.4 
 
Extracted from:  ’Trends in cancer incidence in Singapore 1968/1992 and Cancer 
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Fig.1.1-2. Ten most frequent cancers in females in Singapore, 1993-1997   
































Fig 1.1-3. Age-specific incidence of ovarian cancer in Singapore, 1993-1997 (Chia 




1.1.4 Histologic Type 
 
   Three main types of ovarian cancer have been identified as epithelial, germ cell and 
sex cord-stromal tumours, and age has influence on the pattern of these tumour 
incidences (Cramer et al 1981). The incidence of epithelial tumours increases with 
age and are more common in middle-aged women while germ cell tumours peaks in 
early postpubertal life and does occur constantly at older ages. The common epithelial 
ovarian cancer is derived from the ‘surface epithelium’ of the ovary and the tumour is 
not always homogenous as it consists of the presence of two or even three cell types, 
the neoplasm is classified on the basis of its predominant cellular element (Scully 
1983). Germ cell tumours are frequent at younger ages of below 40 years (Koper et al 
1996). The tumour is associated with nongestational ovarian choriocarcinoma and 
other  germ-cell elements:  dysgermonia,  embryonal carcinoma or immature teratoma  
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(Piver 1983). Sex cord-stromal tumours increase in incidence with increasing age 
(Cramer et al 1981). The sex cord-stromal tumour is generally accepted to be made up 
of a group of cells in the developing gonads and includes all neoplasms which contain 
these various cellular elements alone, or in  combination and in varying degrees of 
differentiation (Scully 1983). In children, ovarian cancers are usually germ cell 
tumours and are rarely of sex cord-stromal tumour  type.  Epithelial  tumours  occur   
after  puberty  and  account  for   increasing numbers of ovarian cancers with 
increasing age. About 90-95% epithelial tumours are seen above the age of 35 years 
(Weiss et al 1977) and small variations of different subtypes are prevalent at different 
ages  (Parkin et al 1988, Cramer et al 1981). Low malignant potential or borderline is 




1.1.5  Reproductive and Endocrine Factors 
   The risk of ovarian cancer is weakly associated to age at menarche and hardly to 
menopause, the risk decreases as the age at menarche increases. Nulliparity is an 
increased risk while lactation is protective (Harlap 1993). The risk of ovarian cancer 
increased with the number of ovulations in a woman’s lifetime (Risch et al 1983; 
Whittemore et al 1989; Booth et al 1989;), a history of infertility or low parity (Joly et 
al 1974 ;McGowan et al 1979; Hildreth et al 1981, Booth et al 1989). Nasca et al 
(1984) found a higher risk in women who had tried to conceive but had failed. A 
strong correlation exist between family history of gynaecologic malignancy, either 
ovarian or endometrial and later development of ovarian cancer (McGowan et al 
1979; Hildreth et al 1981). The odd ratio for positive family history is 18 times greater  
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than for patients with negative family history (Hildreth et al 1981). Late menopause, 
prolonged ovulatory age, increased number of spontaneous abortions and severe 
premenstrual symptomatology all have been related to risk factors (Joly et al 1974; 
McGowan et al 1979; Hildreth et al 1981). Others have associated ovarian cancer risk 
to hormone therapy for inducing ovulation in infertility (Shu et al 1989a; Dietl 1991). 
Since these  drugs elevate  gonadotrophin levels and cause superovulation, the reports 
on the association between the use of fertility drugs and ovarian cancer is conflicting 
(Bristow & Karlan 1996; Glud et al 1998). 
 
1.1.6 Oral Contraceptives 
    Numerous case-control studies have shown that the risk of epithelial ovarian cancer 
is reduced by about 40% in women who have used oral contraceptives (Prentice & 
Thomas 1987) and about 50% in those who have used for five or more years (WHO  
1989). Depending on the duration of use, the protective effect persists for ten or more 
years after discontinuation and is one of the strongest and most consistent features of 
the epidemiology of the disease (WHO 1989; Parazzini et al 1991). However, the pill 
gives no protection  against  non-epithelial  tumours, at  least in  younger women 
(Casagrande  et  al  1983; Westhoff  et  al  1988; Shu et al 1989a,  ).  The  decline  in  
the incidence of ovarian cancer and mortality in developed countries have been 
reported in several studies. This decline has been associated with the potential 
protective effects of oral contraceptives which were introduced in the 1960s and used 
worldwide (Adami et al 1990; Negri et al 1991; Coleman et al 1993; Ries 1993; 
Devesa et al 1995; Dos Santos et al 1995).  
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1.1.6-1  Other Contraceptives 
    Reports investigating into methods of birth control other than oral contraceptives 
have not shown any consistency in their relation to ovarian cancer. Diaphgrams and 
condoms, similarly with intra-uterine devices  (IUCD) (Cramer 1982a, Booth et al 
1989; Chen et al 1992), and vasectomies (Booth et al 1989) have not shown any 
significant relationship to ovarian cancer. Tubal  sterilization  and  hysterectomy  with  
oophorectomy have been associated with reduced risk (Mori et al 1984; Booth et al 
1989; Koch et al 1988; Irwin et al 1991) while women with intact ovaries after 
hysterectomy have a lower-than-average risk of ovarian cancer. Hysterectomy and 
tubal sterilization are associated with protection for at least 20 years although it may 
wane thereafter (Irwin et al 1991; Miracle-McMahill et al 1997).  
 
1.1.7  Postmenopausal Estrogen Therapy 
   Decreased risk in ovarian cancer could be associated with the use of exogenous 
estrogen, hormone replacement therapy (HRT) which reduces the high gonadotrophin 
levels of postmenopausal women. Few studies have shown such a reduction and a few 
with positive association (Ries et al 1998) while others have not observed such a 
relationship with HRT and ovarian cancer (Harlap 1993;  Rodriguez et al 1997; Weiss 
et al 1982; Hempling et al 1997). The relative risk varies between 0.5 and 1.6 in 
eleven case-control studies  (Annegers et al 1979; Hildreth et al 1981; La Vecchia et 
al 1982; Weiss et al 1982; Cramer et al 1983b; Tzonou et al 1984; Mori et al 1984;  
Harlow et al 1988; Wu et al 1988; Booth et al 1989; Hartge et al 1989). Enhanced risk 
were not seen in six studies (Hildreth et al 1981; Weiss et al 1982; La Vecchia et al 
1982;   Wu et al  1988;   Hartge et al  1989;  Booth et al 1989)  one   study   suggested  
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enhanced risk for estrogen used for more than five years (Cramer et al 1983b). 
Rodriguez et al (1997) suggested that long-term use of estrogen replacement therapy 
might increase the risk of fatal ovarian cancer. An association of ovarian cancer has 
also been suggested with the use of stilbestrol (Hoover et al 1977). 
1.1.8  Talc 
    Asbestos is an accepted cause of mesothelioma (Selikoff et al 1965) and was a 
contaminant in talcum powder prior to the mid- 1970s (Hildick-Smith 1976). Ovarian 
cancer is more common in women with asbestosis (Newhouse et a 1972) and 
occupational exposure to talc has been associated with lung disease but there is a 
controversy whether talc induces disease in humans (Hildick-Smith 1976). Enhanced 
risk  of  ovarian   cancer  has  been  associated  with  the  use of  talc  on the perineum  
(Cramer et al 1982b; Whittemore et al 1988; Chen et al 1992) and is influenced by 
dose response effect, duration of use or with frequency of use. In contrast, talc used 
on diaphragms and condoms is not associated with increased ovarian cancer risk 
(Cramer et al 1982b; Hartge et al 1983; Cook et al 1997). 
 
1.1.8-1 Dietary Factors 
 
   Excessive dietary intake of animal fat or red meat has been reported to enhance the 
risk of epithelial ovarian cancer (Byers et al 1983; La Vecchia et al 1987; Shu et al 
1989). Similarly protective roles have been suggested for dietary fish, vegetables and 
carbohydrates (La Vecchia et al 1987; Shu et al 1989b). These associations are found 
to be weak and there are too few studies to draw any firm conclusions (Harlap 1993). 
Cramer and his co-workers (1989) proposed that an increased risk of epithelial 
ovarian cancer might be seen in populations that consume a high fat-galactose diet but  
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lack the enzyme galactose-1-phosphate uridyltransferase to break down the galactose 
to glucose, thus exposing the ovary to long periods of high galactose concentration.  
    Alcohol drinking has been suggested to be protective against ovarian cancer 
especially  in young  women (Byers et al 1983). However, the  large population-based  
CASH study (Gwinn et al 1986) found no such effects of alcohol, similarly for 
smoking in preventing ovarian cancer (Byers et al 1983; Tzonou et al 1984; Franks et 
al 1987). 
1.1.8-2  Mumps and Other Infectious Diseases 
   The association between past history of mumps and ovarian cancer have been 
reported by others (Menczer et al 1979; McGowan et al 1979; Cramer et al 1983a; 
Tzonou et al 1984; Cramer 1985; Shu et al 1989a; Chen et al 1992). The association 
of rubella, measles, influenza/pneumonia and shingles have also been reported 
(Wynder et al 1969; Risch et al 1983; Lesher et al 1985; Gwinn et al 1990). These 
highly speculative reports on the association between viral infections, including 
mumps and increased risk of ovarian cancer have been conflicting. Menczer and his 
group in Israel (1979) demonstrated low mumps antibody in women with ovarian 
cancer including patients after chemotherapy whilst another group in China (Chen et 
al 1992) reported high antibody titres when compared with controls.  
1.1.8-3 Blood Group 
   Carcinoma of the ovary was reported to be associated with ABO blood group 
system. Osborne and DiGeorge (1963) selected neoplastic disease of the ovary for this 
association study, and concluded that ovarian neoplasms that was associated with 
blood group A have a glandular type of epithelium and those from other blood groups  
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are solid rather than cystic. Bjorkholm (1984) also reported an increased association 
of ovarian cancer in women with blood group A.  
1.1.8-4  Inflammation 
 It has been suggested that other additional mechanism that may underlie ovarian 
cancer is inflammation. Concomitant rapid DNA turnover and defective repair, 
oxidative stress and raised bioactive substances may contribute to this disease. 
Inflammation of both the epithelium and follicle are associated with incessant 
ovulation and local pelvic inflammation may also increase risk. However, further data 
is required to confirm the hypothesis that inflammation is a central biologic process in 
ovarian cancer risk (Ness & Cottreau 1999).  
1.1.9  Hereditary Factors  
   The aetiology of ovarian cancer is unknown but hereditary disorders of ovarian 
neoplasms have been extensively reviewed (Lynch and Kullander 1987) and is 
thought to account for 5% to 10% of all ovarian cancers. Familial ovarian cancer is 
not a rare occurrence and is associated with two conditions; site-specific, the most 
common form which is restricted to the ovarian cancer and the breast/ovarian cancer 
syndrome with clustering of ovarian and breast cancer cases in extended pedigrees 
(Lynch et al 1978). Familial ovarian cancer showed significantly lower age onset than 
in the general population (Lynch et al 1993, Goldberg et al 1997). Ovarian cancer is 
strongly associated with other cancers within families especially in ovarian (Hildreth 
et al 1981; Cramer et al 1983b; Tzonou et al 1984), prostate (Cramer et al 1983c; 
Koch et al 1988), breast (McGowan et al 1979; Hildreth et al 1981; Koch et al 1988; 
Schildkraut  et  al 1988;  Thompson  and  Schildkraut 1991;  Parazzini  et  al 1992 ),  
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colorectal (Tzonou et al 1984; Schildkraut et al 1988; Goldgar et al 1994), lung and 
other reproductive cancers in first-degree relatives of either sex (McGowan et al 1979; 
Cramer et al 1983b; Mori et al 1984; Schildkraut et al 1988), For women who have a 
first-degree relative with ovarian cancer may have as high as 50% chance of 
developing this familial disease compared to a 1.4% (1 in 70) chance for women 
without a family history. Those with breast cancer, relative estimates have varied 
from 0.6 to 6.1 (Hildreth et al 1981, Cramer et al 1983c; Koch et al 1988); mostly 
above one. A family history of endometrial cancer probably might not raise the risk of 
ovarian cancer (Schildkraut et al 1989) although it did in some studies (Hildreth et al 
1981; Tzonou et al 1984). The genetics of ovarian carcinoma is not well documented. 
Cytogenetic investigations revealed alterations in chromosomes 1, 3, 6 and 11 which 
are frequently associated with ovarian cancer (Atkin and Pickthall 1977; Wake et al 
1980; Whang-Peng et al 1984). 
    A candidate gene for BRCA1 was identified by positional cloning in 1994 (Miki et 
al) and confirmed by mutation analysis in high-risk breast cancer families (Castilla et 
al 1994; Futreal et al 1994; Friedman et al 1994). BRCA1 gene was isolated since it 
was first mapped to chromosome arm 17q in 1990 by linkage analysis (Hall et al 
1990; Narod et al 1991). A second breast cancer susceptible gene, BRCA2, was 
localised through linkage studies to the long arm of chromosome 13 and cloned  
(Wooster et al 1994). It accounts for 35% of hereditary breast cancer and is also  
associated  with  male  breast  cancer,  ovarian,  prostate  and  pancreatic cancers 
(Wooster et al 1994; Gayther et al 1995). These genes together account for about 75% 
of strong family history for breast and ovarian cancers. BRCA1 accounts for 
approximately 45% of families with significantly high breast cancer incidence and at  
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least 80% of families with increased incidence of both early-onset breast cancer and 
ovarian  cancer  (Easton et al 1993 a,b; Simard et al 1994).  BRCA2  mutation  carriers  
have a life time risk of breast cancer of about 85% but their risk for ovarian cancer is 
lower (10%-20%) (Easton et al 1993b, 1995). Males carrying the mutated BRCA1 
gene has a three-fold increased risk of prostate cancer, and males and females at a 
four-fold increased risk of colon cancer (Ford et al 1994). More than 100 mutations in 
the gene have been described, many of which result in premature truncation of protein 
transcription (Miki et al 1994). Although   BRCA1  has  been  identified, more  genes 
involved in gynaecologic malignancies remain to be discussed, and the clinical 
significance of the cancer gene already known is still in its infancy (Lynch et al 1998). 
 
   The International Federation of Gynecology and Obstetrics (FIGO) staging of 
primary carcinoma of the ovary and the 4-stages of ovarian cancer (stages I to IV) 
























1.1.10.  Table 1.1-4.  FIGO Staging of primary carcinoma of the ovary. 
 
 FIGO Stage  Tumor Characteristics 
 
  I  Growth limited to the ovaries 
IA Growth limited to one ovary; no ascites; no tumor on the external 
surface; capsule intact 
IB Growth limited to both ovaries; no ascites; no tumor on the external 
surfaces; capsule intact 
IC Tumor either stage IA or IB but with tumor on surface on one or both 
ovaries; or with capsule ruptured; or with ascites present containing 
malignant cells; or with positive peritoneal washings 
   
II  Growth involves one or both ovaries with pelvic extension   
 IIA Extension or metastases to the uterus or tubes 
 IIB Extension to other pelvic tissues 
IIC Tumor either stage IIA or IIB, but with tumor on surface of one or both 
ovaries; or with capsule ruptured; or with ascites present containing 
malignant cells; or with positive peritoneal washings 
 
III Tumor involves one or both ovaries with peritoneal implants 
outside the pelvis and/or positive retroperitoneal or inguinal nodes. 
Superficial liver metastasis equals stage III. Tumor is limited to 
the true pelvis but with histologically proven malignant extension 
to small bowel or omentum 
IIIA Tumor grossly limited to the true pelvis with negative nodes but with 
histologically confirmed microscopic seeding of abdominal peritoneal 
surfaces 
IIIB Tumor of one or both ovaries with histologically confirmed implants of 
abdominal peritoneal surfaces, none exceeding 2 cm in diameter; nodes 
are negative 
IIIC Abdominal implants greater than 2 cm in diameter or positive  
retroperitoneal or inguinal nodes 
   
IV Growth involves one or both ovaries, with distant metastases. If 
pleural effusion is present, there must be positive cytology to allot 
a case to stage IV. Parenchymal liver metastasis equals stage IV. 
  
 































































The 4 Stages of Ovarian Cancer 
 
I    Confined to Ovary 
II   Spread Outside of Ovary Confined to Pelvis 
III   Spread to Abdomen 
IV   Spread to Liver or Beyond Abdomen 
 
The four stages of Ovarian Cancer  (Piver and  Wild 1997).  
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1.1.11  MORTALITY TRENDS IN OVARIAN CANCER 
 
   It is important to know the limits and uncertainties of cancer death certification and 
their trends over time particularly for the elderly, and there is no widespread nor 
generalised upward trend in cancer mortality except in lung and other tobacco-
related neoplasms. Generally, cancer mortality trends over the last four decades have 
been favourable for elderly women (Levi et al 1996) 
. 
   Five-year survival rates for patients with epithelial ovarian cancer remain fairly 
static at between 30 to 40%, despite the use of aggressive treatment regimens 
including, cytoreductive surgery; multi-agent chemotherapy regimens; salvage 
therapies (Silverberg et al 1990, Miller et al 1993). The lack of progress may be 
usually attributed to the advanced stage of the disease at the time of diagnosis and 
improvement in survival rates may occur when screening methods are developed to 
screen populations at high risk for ovarian cancer. 
    The distribution of cancer of the ovary is similar to that reported for breast cancer 
with high incidence in the United Kingdom and Ireland. In Europe, concentrations of 
high-risk regions were seen with Denmark having the highest incidence (11.2) and 
above-average rate in Germany. A clear North-South gradient incidence rate is seen in 
Europe with lowest rates in much of France and Italy. In the United States, Japan and 
Australia, ovarian cancer accounts for 6.0%, 2.9% and 6.0% respectively of all cancer 
deaths in females (Smans et al (eds) 1992). 
    Between 1983 - 1987, the highest mortality rates per 100,000 women for ovarian  
cancer  in  central  Europe  were  found  in Czechlovaskia (8.52), East Germany 
(8.24), Austria (8.23) with median mortality rates in West Germany (7.84), Hungary 
(7.22)  and  Poland (6.44),  Bulgaria  (4.94),  Romania  (4.63) and  the  lowest  rate in  
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Yugoslavia (4.35). The highest ovarian cancer mortality worldwide were found in 
Denmark (10) and the lowest in Japan and south of Europe (about 3). The lowest 
incidence rates (<4) were found in African and Asian registries as well as in native 
Kuwaitis. The incidence in central Europe ranged from 5.6 (Szaboles, Hungary) to 
13.6 (Bohemia and Moravia, Czechlovaski) (Zatonski et al 1996). 
    Epithelial ovarian cancer is associated with the highest mortality rate of all 
gynaecologic malignancies.  No symptoms or signs are manifested in the early stages 
of the disease. The prognosis of the disease is generally poor as reflected by the lower 
than 30% five-year survival rate (Office of Pop. Cons. & Surveys 1993 [England & 
Wales]) and between 30% to 40% (Silverberg et al 1990). The poor prognosis of the 
disease is mainly due to the advanced stage of the disease (Stage III and IV) 
diagnosed in more than 75% of cases of ovarian cancer despite advances in surgery 
and chemotherapy (Miller et al 1993). The prognosis of patients with mucinous 
tumour is more favourable than in patients with serous tumours, and patients with 
clear cell tumours was worse (Bjorge et al 1998b; Tammela et al 1998). 
    Ovarian cancer mortality among the elderly in developed countries is rising, with 
increasing  age-dependency (Levi et al 1996; Koper et al 1996)  whereas mortality in 
the younger-age group is declining (Koper et al 1996).  The certified  mortality  rates  
from  ovarian cancer in women aged between 65 and 84 years were between 30 and 
50/100,000 in most northern European and American countries, Australia and New 
Zealand. Lower mortality rates in eastern Europe and Japan in the 1950s and 1960s 
were seen with appreciable rise in the early 1990s which remained generally lower 
than reported for North America or Europe (Levi et al 1996). In the Netherlands, the 
mortality  rates  declined  from  13.1/100,000  (1969-1973)  to  11.4/100,000  between  
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1989-1993 (Koper et al 1996). In the United States, it was estimated that 26,600 
women will be diagnosed with ovarian cancer in 1995 and 14,500 will die from the 
disease (American Cancer Society 1995; T-Luna & Mitchell 1995). The overall 
ovarian cancer mortality rates had changed little in the United States prior to 1979. 
However, the increasing mortality rates between the period 1979 to 1995 reflects a 
growing aging population, where increase mortality rates were observed in older 
women above 65 years and decreasing mortality in younger women (Oriel et al 1999). 
The overall mortality rates in the United States for the period between 1979 and 1995 
were; Whites (deaths 185,976, rate 9.9/100,000 women); Blacks (deaths 15,319, rate 
8.1/100,000) and others (death 2224, rate 4.9) (Oriel et al 1999).  
    In England and Wales, the age-standardized death rate rose from 11.8 to 
14.2/100,000 between 1950 and 1991. There is a clear divergence in trend between 
the younger and older age group in mortality rates. The death rate trend fluctuated at 
around a mean of 0.8/100,000 in the 15-34 age group between 1950 and 1970 and a 
downward trend from 0.9 (1970) to 0.5/100,000 in 1991. Similar trend was seen in the 
35-54 year age group with a stable mean of 13.5/100,000 between 1950 and 1970 but 
thereafter declined to 9.7/100,000 in 1991. No decline in mortality was observed in 
women above 55 years who experience an increase from 29-35/100,000. The 
mortality rate in the older age group of over 65 years showed an increase from 31 to 
48/100,000 between 1950 and 1991 (Mant and Vessey 1995). 
   At the National Taiwan University Hospital between 1980 -1989, the observed 5-
year survival rate was 29.4% for epithelial ovarian cancer, 51.4% for non-epithelial 
and 64.5% for germ-cell tumours (Chen et al 1994). There is no homogeneous trend 
in the international mortality rates for ovarian cancer (Coleman et al 1993). Japan and  
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Italy showed a rise in mortality between 1955-1985 whilst in Australia and The 
Netherlands, no sustained rise was seen, similarly in Norway. The mortality rate in the 
United States and Canada has fallen over this period. Most countries showed a rising 
mortality trend in 55-84 age group except Denmark where the mortality rates has been 
falling since 1970. Survival rates have increased since the introduction of more 
aggressive treatment modalities in the mid-1970s with extensive surgery followed by 
platinum-based chemotherapy regimens. Short-term survival rate for epithelial 
ovarian cancer has improved but no major improvement in the 5-year survival rate 
were seen (Ries 1993; Balvert-Locht et al 1991; Averette et al 1995; Bjorge et al 
1998a). 
     In Thailand, granulosa cell tumour of the ovary accounted for 5.8% in 620 ovarian 
malignancies during the period of study, 1984 to 1994.  It showed a 5-year survival of 
94% in early stages and 25% in advanced stages with an overall  62%  for  all  stages  
of  the  disease  (Maleemonkol  et  al  1996). The mortality rate from this tumour is 
generally low (11-22%) but it displayed a higher malignant potential in Thailand. 
   The age-standardized ovarian cancer mortality in the elderly between 1955 and 1992 
(Levi et al 1996) is shown in Table 1.1-5. The mortality trends between 1955 and 1985 
in selected countries (Mant and Vessey 1995), the Netherlands between 1954 and 1993 
(Koper et al 1996) and the 5-year survival rate of ovarian cancer in Norway between 











Table 1.1-5.  Age-standardized (65-84 years, world standard) death 
certification rates per 100,000 women from ovarian cancer in various countries, 
1955 – 1992 (Levi et al 1996). 
 
Country           1955-       1990-          %        Country                1955-       1990-      % 
           1959        1992         Increase          1959        1992       Increase 
 
Austria              47.4         49.2     3.9            Spain           1.8  1         8.4        920.6 
Belgium              21.2         44.7 110.9            Sweden                    39.2        44.5          13.6 
Czechoslovakia  24.4         31.6          29.7           Switzerland              40.0        48.0         20.0 
Denmark             49.7        59.2   19.3        UK, England/Wales 33.9        49.1         44.6    
Finland              26.0        37.1          42.8            UK, Scotland            30.1       55.8          85.7 
France              12.9        36.6        182.7            Canada            35.2       37.0            4.9 
Germany             36.1       45.8   26.7       U.S.A.              33.5       41.2          22.9 
Greece                2.9*      15.7         435.0       Japan              3.2        14.5        358.2 
Ireland              14.1       48.9         246.2       Australia           28.2        36.2          28.6 
Italy              10.2       24.4 140.0       New Zealand           34.1        44.9          31.9 
The Netherlands 35.3       53.1   50.3 








































































































Fig.1.1-5.  Mortality from ovarian cancer in international selected countries, 1953-
1987 (upper fig.). Countries that did not show a rise in mortality and (lower fig.) 






















Fig. 1.1-6. Five-year survival of patients with epithelial ovarian cancer in Norway, 






































Fig. 1.1-7.  Age-specific ovarian cancer mortality in the Netherlands, 1954-1993 




1.1.12  Mortality Trends of Cancer in Singapore 
    In Singapore, the comprehensive population-based registry only began in 1968, 
primarily to obtain information on cancer patterns in Singapore. The known published 
mortality rate for ovarian cancer in Singapore for 1965 was 5.0/100,000 per year (10 
deaths), and in 1985 it was 7.4/100,000 per year (26 deaths) in the 30 to 74 year age 
group (Coleman et al 1993). This coincides with increasing incidence of ovarian 
cancers recorded between 1968 and 1997 (Table 1.1-3). 
   Mortality in cancer patients continued to increase in importance over the last 
decade. Of the 75,871 deaths in 1993-1997, malignant neoplasms accounted for 
19,408 cases. Mortality from cancer was 25.6% (1993-7) compared with 14.8% in 
1968-1972. Lung cancer had the highest incidence among all cancers in males and 
females and followed by liver cancer in males and breast cancer in the females (Chia 
et al 2000).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
